IGFBP2 and acute myeloid leukemia: Although a previous study has indicated that the compound anthraquinone-2-sulfonic acid (AQ2S) inhibited the Ran-BP2-type ZF in the RBM5 [38], the activity of this small molecular or pharmacological approaches to inhibit RBM5 or in combination with other drugs, such as venetoclax, needs to be verified in the AML context.